Natco Pharma consolidated net profit declines 22 percent at Rs 62 crore in Q3
New Delhi: Natco Pharma has announced that its consolidated net profit declined by 22 percent to Rs 62 crore for the third quarter ended December 31, 2022.
The Hyderabad-based drug firm had reported a net profit of Rs 80 crore in the October-December quarter of last fiscal.
Total income of the company stood at Rs 513 crore in the period under review as compared with Rs 591 crore in the year-ago period that had a one-time licensing revenue.
The company's board, which met on Thursday, approved an interim dividend of Rs 1.25 per share for the quarter ended December 31, 2022.
Read also: Natco Pharma unveils first generic version of Pomalyst capsules in Australia
Natco Pharma Limited is a vertically integrated and R&D-focused pharmaceutical company engaged in developing, manufacturing, and marketing of finished dosage formulations ("FDF") and active pharmaceutical ingredients ("APIs"). The company focuses primarily on niche therapeutic areas and complex products. Natco markets and distributes its products in over 40 countries.
Natco sells its FDF products in the United States, India, Europe, and the rest of the world ("RoW"). In the API segment, the company has the capabilities to develop and manufacture products with multi-step synthesis, semi-synthetic fusion technologies, high-potency APIs, and peptides.
The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
Read also: Natco Pharma launches Chlorantraniliprole (CTPR) pesticide formulated combination products in India
